Please use this identifier to cite or link to this item: https://doi.org/10.1186/1750-1172-3-11
Title: Adaptive design methods in clinical trials - A review
Authors: Chow, S.-C 
Chang, M
Keywords: clinical trial
human
methodology
phase 2 clinical trial
phase 3 clinical trial
randomization
rare disease
review
statistics
Clinical Trials as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Humans
Random Allocation
Rare Diseases
Research Design
Statistics as Topic
Issue Date: 2008
Publisher: BMC
Citation: Chow, S.-C, Chang, M (2008). Adaptive design methods in clinical trials - A review. Orphanet Journal of Rare Diseases 3 (1) : 11. ScholarBank@NUS Repository. https://doi.org/10.1186/1750-1172-3-11
Rights: Attribution 4.0 International
Abstract: In recent years, the use of adaptive design methods in clinical research and development based on accrued data has become very popular due to its flexibility and efficiency. Based on adaptations applied, adaptive designs can be classified into three categories: prospective, concurrent (ad hoc), and retrospective adaptive designs. An adaptive design allows modifications made to trial and/or statistical procedures of ongoing clinical trials. However, it is a concern that the actual patient population after the adaptations could deviate from the originally target patient population and consequently the overall type I error (to erroneously claim efficacy for an infective drug) rate may not be controlled. In addition, major adaptations of trial and/or statistical procedures of on-going trials may result in a totally different trial that is unable to address the scientific/medical questions the trial intends to answer. In this article, several commonly considered adaptive designs in clinical trials are reviewed. Impacts of ad hoc adaptations (protocol amendments), challenges in by design (prospective) adaptations, and obstacles of retrospective adaptations are described. Strategies for the use of adaptive design in clinical development of rare diseases are discussed. Some examples concerning the development of Velcade intended for multiple myeloma and non-Hodgkin's lymphoma are given. Practical issues that are commonly encountered when implementing adaptive design methods in clinical trials are also discussed. © 2008 Chow and Chang; licensee BioMed Central Ltd.
Source Title: Orphanet Journal of Rare Diseases
URI: https://scholarbank.nus.edu.sg/handle/10635/178235
ISSN: 1750-1172
DOI: 10.1186/1750-1172-3-11
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_1750-1172-3-11.pdf1.14 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

252
checked on Mar 6, 2021

Page view(s)

39
checked on Mar 5, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons